Abstract
Cancer Acute myeloid leukemia is a difficult disease to treat under the best of circumstances, and the subtype containing internal tandem duplication of fms-like tyrosine kinase 3 ( FLT3 -ITD) is particularly challenging. In a high-throughput drug screen, Lam et al. identified homoharringtonine as a candidate treatment for this type of leukemia and confirmed its effectiveness in cancer cells, mouse models, and patients. Promising results were obtained from a phase II clinical trial that included elderly patients and patients for whom all previous treatments had failed. Sci. Transl. Med. 8 , 359ra129 (2016).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
